Company United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-18 EDT 5-day change 1st Jan Change
306 USD +3.02% Intraday chart for United Therapeutics Corporation +10.98% +39.18%

Business Summary

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Number of employees: 1,168

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
1,936 100.0 % 2,328 100.0 % +20.20%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
94.6 %
1,814 93.7 % 2,202 94.6 % +21.39%
Rest of World
5.4 %
122 6.3 % 125 5.4 % +2.54%

Managers

Managers TitleAgeSince
Chief Executive Officer 69 96-06-25
President 52 11-03-31
Director of Finance/CFO 56 12-12-31
Investor Relations Contact - 18-12-31
General Counsel 60 96-06-25

Members of the board

Members of the board TitleAgeSince
Director/Board Member 76 01-12-31
Chief Executive Officer 69 96-06-25
Director/Board Member 81 09-12-31
Director/Board Member 72 15-06-25
Director/Board Member 67 14-11-10
Director/Board Member 90 01-12-31
Director/Board Member 60 02-10-23
Director/Board Member 61 02-12-31
Director/Board Member 60 09-04-28
Director/Board Member 64 18-10-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,250,109 43,536,223 ( 58.63 %) 29,894,415 ( 40.26 %) 58.63 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
11.35 %
5,037,364 11.35 % 1 386 M $
The Vanguard Group, Inc.
10.57 %
4,687,393 10.57 % 1 290 M $
Vanguard Fiduciary Trust Co.
10.56 %
4,683,095 10.56 % 1 288 M $
Wellington Management Co. LLP
7.691 %
3,412,260 7.691 % 939 M $
Avoro Capital Advisor LLC
6.444 %
2,858,888 6.444 % 787 M $
Renaissance Technologies LLC
4.850 %
2,151,714 4.850 % 592 M $
1,935,119 4.362 % 532 M $
Fidelity Management & Research Co. LLC
2.292 %
1,016,988 2.292 % 280 M $
AQR Capital Management LLC
1.909 %
846,955 1.909 % 233 M $
Geode Capital Management LLC
1.867 %
828,271 1.867 % 228 M $

Holdings

NameEquities%Valuation
796,885 3.66% 2,478,312 $
2,869,517 2.23% 944,071 $

Company contact information

United Therapeutics Corp.

1000 Spring Street

20910, Silver Spring

+301 608 9292

http://www.unither.com
address United Therapeutics Corporation(UTHR)
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Company United Therapeutics Corporation